quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·912d
PRRelease
PHAXIAM Therapeutics S.A.. logo

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

PHXM· PHAXIAM Therapeutics S.A..
Health Care
Original source

Companies

  • PHXM
    PHAXIAM Therapeutics S.A..
    Health Care

Related

  • PR521d
    PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
  • SEC773d
    SEC Form 15F-12B filed by PHAXIAM Therapeutics S.A..
  • PR774d
    PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
  • SEC779d
    SEC Form EFFECT filed by PHAXIAM Therapeutics S.A..
  • SEC780d
    SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
  • SEC780d
    SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
  • SEC780d
    SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
  • SEC780d
    SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022